Rose Hill Life Sciences Teams Up With Johns Hopkins University On Exclusive License For Psychedelic Therapies Targeting Post-Neurological Injury Motor Function

Rose Hill Life Sciences, a global company specializing in the research and development of premium psilocybin-based therapies, has entered into an exclusive licensing agreement with Johns Hopkins University. Under this agreement, Rose Hill will gain exclusive rights to intellectual property developed at Johns Hopkins that focuses on enhancing motor function in individuals with neurological injuries through the use of psychedelic therapy. The licensed invention outlines methods aimed at improving motor function in patients who have experienced central nervous system (CNS) injuries. 

These injuries may be acute, subacute, or chronic in nature. In addition, the invention includes approaches for treating focal diaschisis, a disruption in brain activity resulting from localized brain injury offering potential new avenues for recovery in patients affected by neurological damage. This agreement marks an important step in Rose Hill’s strategy to combine neuroscience and psychedelic medicine to develop innovative therapeutic solutions. 

Steven Zeiler, MD, PhD, an associate professor and physician at Johns Hopkins School of Medicine, mentioned, “This license has the potential to transform how we approach stroke recovery. By investigating whether psilocybin can safely enhance neuroplasticity, we hope to uncover new pathways for improving motor function in stroke patients offering them better chances at regaining independence and quality of life.”

Gül Dölen, MD, PhD, Professor and Parson’s Endowed Chair of Neuroscience and Psychology at UC Berkeley and Adjunct Professor of Neuroscience and Neurology at Johns Hopkins University, said in a statement, “Psychedelics have shown remarkable potential to reopen critical periods if harnessed correctly this reopened window of brain malleability, could revolutionize stroke rehabilitation. This license represents an exciting step toward understanding how psilocybin can rewire the brain, potentially leading to more effective and lasting recovery strategies for stroke survivors.”

Domenic Suppa, Co-founder and COO of Rose Hill Life Sciences, stated, “We are committed to unlocking the therapeutic potential of psilocybin across a range of conditions. Partnering with Johns Hopkins to commercialize this intellectual property underscores our dedication to advancing science-driven solutions that could improve the lives of stroke survivors worldwide.”

The collaboration with Johns Hopkins also opens up opportunities for further research into how psychedelics, when used alongside traditional rehabilitation therapies, could support recovery in patients who have suffered strokes or similar neurological events. By securing exclusive rights to this intellectual property, Rose Hill strengthens its position as a leader in the emerging field of psychedelic-assisted treatments, with a focus on developing science-backed approaches that may significantly benefit individuals with serious neurological conditions.